INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice - Poll - MDSpire

INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice

  • By

  • Sameer Sharma

  • Lixian Chen

  • Tianhao Zhou

  • Meenakshi Chawla

  • Anita Ganjoo

  • Shunichiro Okada

  • Salvatore Alesci

  • Krishnan Nandabalan

  • Heather Francis

  • June 9, 2026

  • 0 min

Share

Original Source(s)

INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice

  • by Sameer Sharma, Lixian Chen, Tianhao Zhou, Meenakshi Chawla, Anita Ganjoo, Shunichiro Okada, Salvatore Alesci, Krishnan Nandabalan, Heather Francis

  • June 9, 2026

Related Content

Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B

T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection

Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set